Try a new search

Format these results:

Searched for:

in-biosketch:true

person:stermd01

Total Results:

166


Novel intrapleural therapies for malignant diseases

Haas, Andrew R; Sterman, Daniel H
Pleural malignancies, either primary or metastatic, are common and problematic clinical issues in thoracic oncology and pulmonary medicine. Malignant pleural mesothelioma and metastatic pleural effusions often present late in the course of a disease and have a dramatic impact on the patient's quality of life and survival. Novel approaches to manage mesothelioma and malignant pleural effusions are desperately needed and the pleural space provides a unique platform as an easily accessible body cavity for developing and assessing these treatments and their responses. In this review, we discuss the unique intrapleural chemotherapeutic, immunotherapeutic and genetic treatments that have been investigated, as well as those under current clinical development. While responses have been demonstrated to variable degrees with all these approaches, an integrated multimodality approach incorporating these methods with other anti-neoplastic interventions ultimately will ensure the best responses and patient outcomes.
PMID: 22456231
ISSN: 0025-7931
CID: 1344772

A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma

Sterman, Daniel H; Haas, Andrew; Moon, Edmund; Recio, Adriana; Schwed, Daniel; Vachani, Anil; Katz, Sharyn I; Gillespie, Colin T; Cheng, Guanjun; Sun, Jing; Papasavvas, Emmanouil; Montaner, Luis J; Heitjan, Daniel F; Litzky, Leslie; Friedberg, Joseph; Culligan, Melissa; June, Carl H; Carroll, Richard G; Albelda, Steven M
New therapeutic strategies are needed for malignant pleural mesothelioma (MPM). We conducted a single-center, open-label, nonrandomized, pilot and feasibility trial using two intrapleural doses of an adenoviral vector encoding human IFN-alpha (Ad.IFN-alpha2b). Nine subjects were enrolled at two dose levels. The first three subjects had very high pleural and systemic IFN-alpha concentrations resulting in severe "flu-like" symptoms necessitating dose de-escalation. The next six patients had reduced (but still significant) pleural and serum IFN-alpha levels, but with tolerable symptoms. Repeated vector administration appeared to prolong IFN-alpha expression levels. Anti-tumor humoral immune responses against mesothelioma cell lines were seen in seven of the eight subjects evaluated. No clinical responses were seen in the four subjects with advanced disease. However, evidence of disease stability or tumor regression was seen in the remaining five patients, including one dramatic example of partial tumor regression at sites not in contiguity with vector infusion. These data show that Ad.IFN-alpha2b has potential therapeutic benefit in MPM and that it generates anti-tumor immune responses that may induce anatomic and/or metabolic reductions in distant tumor. Clinical trial registered with www.clinicaltrials.gov (NCT 01212367).
PMCID:3262033
PMID: 21642245
ISSN: 1073-449x
CID: 1344822

Gene therapy for lung neoplasms

Vachani, Anil; Moon, Edmund; Wakeam, Elliot; Haas, Andrew R; Sterman, Daniel H; Albelda, Steven M
Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.
PMCID:3210443
PMID: 22054892
ISSN: 0272-5231
CID: 1344812

Diagnosis of idiopathic tracheal stenosis and treatment with papillotome electrocautery and balloon bronchoplasty [Case Report]

Solly, William R; O'Connell, Richard J; Lee, Hans J; Sterman, Daniel H; Haas, Andrew R
PMID: 21513609
ISSN: 0020-1324
CID: 1344842

Airway complications following lung transplantation

Puchalski, Jonathan; Lee, Hans J; Sterman, Daniel H
There are 6 major types of airway complications following lung transplantation: necrosis and dehiscence, infection, granulation tissue formation, malacia, fistulae, and stenosis. This article reviews the risk factors for developing airway complications after lung transplantation, the clinical features of the complications, and treatment options for these problems.
PMID: 21511095
ISSN: 0272-5231
CID: 1344852

Treatment of a malignant peripheral nerve sheath tumor and its complications through a multidisciplinary approach [Case Report]

McLaughlin, Eamon J; Heuer, Gregory G; Whitmore, Robert G; Birknes, John K; Belasco, Jean; Sterman, Daniel; Low, David W; Storm, Phillip B
The authors report the case of a 14-year-old girl with a residual malignant peripheral nerve sheath tumor after thoracotomy, chemotherapy, and radiation therapy. The residual tumor, which involved the intercostal muscles, aorta, and neural foramina of T4-10, was completely resected through a costotransversectomy and multiple hemilaminotomies with the patient in the prone position and was stabilized using a T1-12 pedicle screw fusion. Postoperatively, the patient developed several infections requiring multiple washouts and prolonged antibiotics. Thirty months after surgery, she developed a bronchocutaneous fistula. The hardware was removed, and a vascularized latissimus dorsi free flap was placed over the lung. She continued to have an air leak and presented 3 weeks later with a 40 degrees left thoracic curve. She returned to the operating room for a T2-L2 fusion with a vascularized fibular graft. On postoperative Day 1, she underwent a bronchoscopy and had her left lower lobe airways occluded with multiple novel one-way endobronchial valves. She is now 5 years out from her tumor resection and 3 years out from her definitive fusion. She has no evidence of residual tumor, infection, or pseudarthrosis and continues to remain asymptomatic.
PMID: 21529197
ISSN: 1933-0707
CID: 1344832

Endobronchial valve treatment for prolonged air leaks of the lung: a case series

Gillespie, Colin T; Sterman, Daniel H; Cerfolio, Robert J; Nader, Daniel; Mulligan, Michael S; Mularski, Richard A; Musani, Ali I; Kucharczuk, John C; Gonzalez, H Xavier; Springmeyer, Steven C
PURPOSE: An endobronchial valve developed for treatment of severe emphysema has characteristics favorable for bronchoscopic treatment of air leaks. We present the results of a consecutive case series treating complex alveolopleural fistula with valves. DESCRIPTION: Patients with air leaks that persisted after treatment gave consent and compassionate use approval was obtained. Bronchoscopy with balloon occlusion was used to identify the airways to be treated. IBV Valves (Spiration, Redmond, WA) were placed after airway measurement. EVALUATION: During a 15-month period, 8 valve placement procedures were performed in 7 patients and all had improvement in the air leak. The median duration of air leakage was 4 weeks before and 1 day after treatment, with a mean of 4.5 days. Discharge within 2 to 3 days of the procedure occurred in 57% of the patients. A median of 3.5 valves (mode, 2.4) were used, and all valve removals were successful. There were no procedural or valve-related complications. CONCLUSIONS: Removable endobronchial valves appear to be a safe and effective intervention for prolonged air leaks.
PMID: 21172529
ISSN: 0003-4975
CID: 1344862

Pilot randomized study comparing two techniques of airway anaesthesia during curvilinear probe endobronchial ultrasound bronchoscopy (CP-EBUS)

Lee, Hans J; Haas, Andrew R; Sterman, Daniel H; Solly, Randy; Vachani, Anil; Gillespie, Colin T
BACKGROUND AND OBJECTIVE: This study evaluates two different techniques for topically anaesthetizing the airway with lidocaine during curvilinear probe endobronchial ultrasound bronchoscopy (CP-EBUS): standard injection through the working channel and spray catheter application. METHODS: This was a randomized, non-blinded, single-centre pilot study. Patients with plans for CP-EBUS under moderate sedation were enrolled. All patients received nebulized lidocaine followed by posterior oropharyngeal lidocaine via atomizer and a cotton ball swab using McGill forceps. Patients were then randomly assigned to lidocaine administration using spray catheter instillation or direct application through the working channel. Lidocaine was administered in a uniform fashion by a single investigator throughout the study. The primary end-point was the number of significant coughing episodes in the first 30 min of bronchoscopy. Other end-points included lidocaine and intravenous sedation medication dosage; severe coughing session; and number of transbronchial needle aspirations. RESULTS: Forty patients were included in the study: 20 patients in each group. The median numbers of coughing episodes in the first 30 min were 1 (spray catheter group) and 2 (standard injection group) (P < 0.004). Six patients in the standard installation group experienced severe coughing sessions, while there was none in the spray catheter group (P = 0.02). There were no statistical differences between the groups in the dosage of lidocaine or intravenous sedation medications used. There were a greater number of transbronchial needle aspirations performed in the spray catheter group (P = 0.008). CONCLUSIONS: Lidocaine delivery via the spray catheter reduced the number of significant coughing episodes compared with standard working channel injection during CP-EBUS. Larger studies are needed to confirm these exploratory findings.
PMID: 20920136
ISSN: 1323-7799
CID: 1344872

Advances in diagnostic bronchoscopy

Haas, Andrew R; Vachani, Anil; Sterman, Daniel H
Diagnostic bronchoscopy has undergone two major paradigm shifts in the last 40 years. First, the advent of flexible bronchoscopy gave chest physicians improved access to the tracheobronchial tree with a rapid learning curve and greater patient comfort compared with rigid bronchoscopy. The second paradigm shift has evolved over the last 5 years with the proliferation of new technologies that have significantly enhanced the diagnostic capabilities of flexible bronchoscopy compared with traditional methods. At the forefront of these new technologies is endobronchial ultrasound. In its various forms, endobronchial ultrasound has improved diagnostic yield for pulmonary masses, nodules, intrathoracic adenopathy, and disease extent, thereby reducing the need for more invasive surgical interventions. Various navigational bronchoscopy systems have become available to increase flexible bronchoscope access to small peripheral pulmonary lesions. Furthermore, various modalities of airway assessment, including optical microscopic imaging technologies, may play significant roles in the diagnosis of a variety of pulmonary diseases in the future. Finally, the combination of new diagnostic bronchoscopy technologies and novel approaches in molecular analysis and biomarker assessment hold promise for enhanced diagnosis and personalized management of many pulmonary disorders. In this review, we provide a contemporary review of diagnostic bronchoscopy developments over the past decade.
PMCID:3159074
PMID: 20378726
ISSN: 1073-449x
CID: 1344902

Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection [Case Report]

Bajaj, Navkaranbir S; Watt, Christopher; Hadjiliadis, Denis; Gillespie, Colin; Haas, Andrew R; Pochettino, Alberto; Mendez, James; Sterman, Daniel H; Schuchter, Lynn M; Christie, Jason D; Lee, James C; Ahya, Vivek N
In the current era of organ shortages and long wait times for life-saving transplants, marginal or extended donors are increasingly being considered; one such category of marginal organs is from donors with a previous history of malignancy. Melanoma in particular has been associated with increased risk of developing late recurrence. In this report, we describe a case of fatal donor melanoma transmission to a 64-year-old lung transplant recipient 32 years after surgical excision of the melanoma. Based on this report and review of the available literature, we conclude that a history of donor melanoma, regardless of the stage and time interval from 'curative' surgical resection, should remain a strong relative contraindication to transplantation.
PMID: 20444242
ISSN: 0934-0874
CID: 1344892